Stefan Rebhandl
Overview
Explore the profile of Stefan Rebhandl including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
208
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Akimova E, Gassner F, Schubert M, Rebhandl S, Arzt C, Rauscher S, et al.
Nucleic Acids Res
. 2021 Feb;
49(5):2598-2608.
PMID: 33591315
Aberrant end joining of DNA double strand breaks leads to chromosomal rearrangements and to insertion of nuclear or mitochondrial DNA into breakpoints, which is commonly observed in cancer cells and...
2.
Catakovic K, Gassner F, Ratswohl C, Zaborsky N, Rebhandl S, Schubert M, et al.
Oncoimmunology
. 2018 Jan;
7(1):e1371399.
PMID: 29296521
While research on T cell exhaustion in context of cancer particularly focuses on CD8+ cytotoxic T cells, the role of inhibitory receptors on CD4+ T-helper cells have remained largely unexplored....
3.
Gassner F, Schubert M, Rebhandl S, Spandl K, Zaborsky N, Catakovic K, et al.
Mol Cancer Res
. 2017 Dec;
16(3):428-438.
PMID: 29222170
Cancer is a genetic disease caused by mutations and chromosomal abnormalities that contribute to uncontrolled cell growth. In addition, cancer cells can rapidly respond to conventional and targeted therapies by...
4.
Zaborsky N, Gassner F, Asslaber D, Reinthaler P, Denk U, Flenady S, et al.
Oncotarget
. 2016 Jul;
7(31):49459-49469.
PMID: 27385215
Chronic lymphocytic leukemia develops within a complex network driven by genetic mutations and microenvironmental interactions. Among the latter a complex interplay with the immune system is established by the clone....
5.
Rebhandl S, Geisberger R
Eur J Immunol
. 2015 Jul;
45(8):2208-11.
PMID: 26151367
The activation induced deaminase (AID) catalyses the two key events underlying humoral adaptive immunity: class switch recombination and somatic hypermutation of antibody genes in B lymphocytes. AID accomplishes this task...
6.
Rebhandl S, Huemer M, Greil R, Geisberger R
Oncoscience
. 2015 Jun;
2(4):320-33.
PMID: 26097867
Mutations are the basis for evolution and the development of genetic diseases. Especially in cancer, somatic mutations in oncogenes and tumor suppressor genes alongside the occurrence of passenger mutations have...
7.
Gassner F, Zaborsky N, Catakovic K, Rebhandl S, Huemer M, Egle A, et al.
Br J Haematol
. 2015 May;
170(4):515-22.
PMID: 25940792
Although chronic lymphocytic leukaemia (CLL) is a B cell malignancy, earlier studies have indicated a role of T cells in tumour growth and disease progression. In particular, the functional silencing...
8.
Huemer M, Rebhandl S, Zaborsky N, Gassner F, Hainzl S, Weiss L, et al.
Eur J Immunol
. 2014 Sep;
44(12):3747-57.
PMID: 25179679
The activation-induced cytidine deaminase (AID) mediates somatic hypermutation and class switch recombination of the Ig genes by directly deaminating cytosines to uracils. As AID causes a substantial amount of off-target...
9.
Rebhandl S, Huemer M, Zaborsky N, Gassner F, Catakovic K, Felder T, et al.
Eur J Immunol
. 2014 Mar;
44(7):2175-87.
PMID: 24668151
Activation-induced deaminase (AID) is a DNA-mutating enzyme that mediates class-switch recombination as well as somatic hypermutation of antibody genes in B cells. Due to off-target activity, AID is implicated in...
10.
Gassner F, Zaborsky N, Neureiter D, Huemer M, Melchardt T, Egle A, et al.
Haematologica
. 2014 Feb;
99(5):67-9.
PMID: 24561794
No abstract available.